# AstraZeneca plc 3.6% potential upside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-3.6-potential-upside-indicated-by-deutsche/4121127459
- Published: 2023-09-19T14:04:05+01:00
- Author: Charlotte Edwards

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**
with ticker ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
now has a potential upside of 3.6% according to Deutsche.
Deutsche set a target 
price of 11,000 GBX for the company, which when compared to the AstraZeneca plc 
share price of 10,614 GBX at opening today (19/09/2023) indicates a potential upside
of 3.6%. Trading has ranged between 9,499 (52 week low) and 12,828 (52 week high)
with an average of 1,471,870 shares exchanging hands daily. The market capitalisation
at the time of writing is £164,274,650,540.AstraZeneca PLC is a science-led biopharmaceutical
company. The Company focuses on the discovery, development, and commercialization
of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including
cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline
forms a portfolio of investigational therapies in various stages of clinical development
and includes the Alexion Rare Disease portfolio comprising approximately 178 projects.
Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence,
Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include
Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include
Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include
United Kingdom, Rest of Europe, the Americas and Asia, Africa and Australasia. It
is also focused on discovering, developing, and manufacturing of T-cell receptor
therapies.

Share on: